Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.: Strategic Focus on R&D Spending

R&D Spending: Neurocrine's Rapid Ascent vs. Bausch's Steady Growth

__timestampBausch Health Companies Inc.Neurocrine Biosciences, Inc.
Wednesday, January 1, 201424600000046425000
Thursday, January 1, 201558280000081491000
Friday, January 1, 201645500000094291000
Sunday, January 1, 2017366000000121827000
Monday, January 1, 2018414000000160524000
Tuesday, January 1, 2019471000000200000000
Wednesday, January 1, 2020452000000275000000
Friday, January 1, 2021465000000328100000
Saturday, January 1, 2022529000000463800000
Sunday, January 1, 2023604000000565000000
Monday, January 1, 2024731100000
Loading chart...

In pursuit of knowledge

Strategic Focus on R&D Spending: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and Bausch Health Companies Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Bausch Health's R&D expenses grew by approximately 145%, peaking in 2023. Meanwhile, Neurocrine Biosciences, Inc. showcased a remarkable increase of over 1100% in the same period, reflecting a strategic pivot towards aggressive innovation. By 2023, Neurocrine's R&D spending nearly matched Bausch Health's, highlighting its rapid ascent in the industry. This trend underscores the dynamic nature of pharmaceutical R&D, where strategic investments can redefine market positions. As these companies continue to innovate, their R&D strategies will be pivotal in shaping their future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025